JIXING Announces Receipt of Breakthrough Therapy Designation for Aficamten in China
NMPA-granted Breakthrough Therapy Designation for the treatment of symptomatic obstructive hypertrophic cardiomyopathy based on results of REDWOOD-HCM and China Phase I study. Ji Xing Pharmaceuticals...